Skip to main content
Erschienen in: Supportive Care in Cancer 9/2005

01.09.2005 | Original Article

Use of complementary and alternative medicine by patients with urologic cancer: a prospective study at a single Japanese institution

verfasst von: Koji Yoshimura, Nobufumi Ueda, Kentaro Ichioka, Yoshiyuki Matsui, Akito Terai, Yoichi Arai

Erschienen in: Supportive Care in Cancer | Ausgabe 9/2005

Einloggen, um Zugang zu erhalten

Abstract

Objectives

We prospectively evaluated the prevalence and predictors of complementary medicine (CAM) use among Japanese patients with urologic cancer 1 year after diagnosis.

Patients and methods

A total of 349 patients with newly diagnosed urologic cancer answered a self-administered questionnaire on CAM use 1 year after diagnosis. General-health-related quality of life (GHQL) of the patients was also assessed at diagnosis and 1 year after diagnosis using the Medical Outcome Study Short Form-36 (SF-36). The overall prevalence, types of CAM used, and costs of CAM were assessed. The effects of several variables including GHQL at baseline and 1 year after treatment on the prevalence of use of CAM were evaluated.

Results

A total of 164 respondents (47%) admitted using some type of CAM, of which 73 (45%) had used multiple types. “Health food,” in particular extract from Agaricus blazei, was the most common type of CAM used. CAM users had significantly lower scores for social function, general health perception, and vitality domains than CAM non-users 1 year after diagnosis. This tendency was more marked in users of multiple types of CAM.

Conclusions

“Health food,” including extract from A. blazei, was the most commonly used CAM in Japan. The prevalence of CAM use did not differ between patients with prostate cancer and those with urologic cancer other than prostrate cancer. CAM users, especially those who used multiple types of CAM, had lower GHQL scores than non-users of CAM.
Literatur
1.
Zurück zum Zitat Eisenberg DM, Kessler RC, Foster C et al (1993) Unconventional medicine in the United States: prevalence, costs, and patterns of use. N Engl J Med 328:246–252CrossRefPubMed Eisenberg DM, Kessler RC, Foster C et al (1993) Unconventional medicine in the United States: prevalence, costs, and patterns of use. N Engl J Med 328:246–252CrossRefPubMed
2.
Zurück zum Zitat Lippert MC, McClain R, Boyd JC et al (1999) Alternative medicine use in patients with localized prostate carcinoma treated with curative intent. Cancer 86:2642–2648 Lippert MC, McClain R, Boyd JC et al (1999) Alternative medicine use in patients with localized prostate carcinoma treated with curative intent. Cancer 86:2642–2648
3.
Zurück zum Zitat Kao GD, Devine P (2000) Use of complementary health practices by prostate carcinoma patients undergoing radiation therapy. Cancer 88:615–619 Kao GD, Devine P (2000) Use of complementary health practices by prostate carcinoma patients undergoing radiation therapy. Cancer 88:615–619
4.
Zurück zum Zitat Nam RK, Fleshner N, Rakovitch E et al (1999) Prevalence and patterns of the use of complementary therapies among prostate cancer patients: an epidemiological analysis. J Urol 161:1521–1524CrossRefPubMed Nam RK, Fleshner N, Rakovitch E et al (1999) Prevalence and patterns of the use of complementary therapies among prostate cancer patients: an epidemiological analysis. J Urol 161:1521–1524CrossRefPubMed
5.
Zurück zum Zitat Wilkinson S, Gomella LG, Smith JA et al (2002) Attitudes and use of complementary medicine in men with prostate cancer. J Urol 168:2505–2509CrossRefPubMed Wilkinson S, Gomella LG, Smith JA et al (2002) Attitudes and use of complementary medicine in men with prostate cancer. J Urol 168:2505–2509CrossRefPubMed
6.
Zurück zum Zitat Boon H, Westlake K, Stewart M et al (2003) Use of complementary/alternative medicine by men diagnosed with prostate cancer: prevalence and characteristics. Urology 62:849–853CrossRefPubMed Boon H, Westlake K, Stewart M et al (2003) Use of complementary/alternative medicine by men diagnosed with prostate cancer: prevalence and characteristics. Urology 62:849–853CrossRefPubMed
7.
Zurück zum Zitat Diefenbach MA, Hamrick N, Uzzo R et al (2003) Clinical, demographic and psychosocial correlates of complementary and alternative medicine use by men diagnosed with localized prostate cancer. J Urol 170:166–169CrossRefPubMed Diefenbach MA, Hamrick N, Uzzo R et al (2003) Clinical, demographic and psychosocial correlates of complementary and alternative medicine use by men diagnosed with localized prostate cancer. J Urol 170:166–169CrossRefPubMed
8.
Zurück zum Zitat Ponholzer A, Struhal G, Madersbacher S (2003) Frequent use of complementary medicine by prostate cancer patients. Eur Urol 43:604–608 Ponholzer A, Struhal G, Madersbacher S (2003) Frequent use of complementary medicine by prostate cancer patients. Eur Urol 43:604–608
9.
Zurück zum Zitat Hall JD, Bissonette EA, Boyd JC et al (2003) Motivations and influences on the use of complementary medicine in patients with localized prostate cancer treated with curative intent: results of a pilot study. BJU Int 91:603–607CrossRefPubMed Hall JD, Bissonette EA, Boyd JC et al (2003) Motivations and influences on the use of complementary medicine in patients with localized prostate cancer treated with curative intent: results of a pilot study. BJU Int 91:603–607CrossRefPubMed
10.
Zurück zum Zitat Beebe-Dimmer JL, Wood DP Jr, Gruber SB et al (2004) Use of complementary and alternative medicine in men with family history of prostate cancer: a pilot study. Urology 63:282–287CrossRefPubMed Beebe-Dimmer JL, Wood DP Jr, Gruber SB et al (2004) Use of complementary and alternative medicine in men with family history of prostate cancer: a pilot study. Urology 63:282–287CrossRefPubMed
11.
Zurück zum Zitat Ware JE, Scherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. conceptual framework and item selection. Med Care 30:473–483PubMed Ware JE, Scherbourne CD (1992) The MOS 36-item short-form health survey (SF-36). I. conceptual framework and item selection. Med Care 30:473–483PubMed
12.
Zurück zum Zitat Fukuhara S, Koshinski M (1998) Psychometric and clinical tests of validity of the Japanese SF-36 health survey. J Clin Epidemiol 51:1045–1053PubMed Fukuhara S, Koshinski M (1998) Psychometric and clinical tests of validity of the Japanese SF-36 health survey. J Clin Epidemiol 51:1045–1053PubMed
13.
Zurück zum Zitat Yoshimura K, Ichioka K, Terada N et al (2003) Use of complementary and alternative medicine by patients with localized prostate carcinoma: study at a single institute in Japan. Int J Clin Oncol 8:26–30CrossRefPubMed Yoshimura K, Ichioka K, Terada N et al (2003) Use of complementary and alternative medicine by patients with localized prostate carcinoma: study at a single institute in Japan. Int J Clin Oncol 8:26–30CrossRefPubMed
14.
Zurück zum Zitat Liu JM, Chu HC, Chin YH et al (1997) Cross sectional study of use of alternative medicines in Chinese cancer patients. Jpn J Clin Oncol 27:37–41 Liu JM, Chu HC, Chin YH et al (1997) Cross sectional study of use of alternative medicines in Chinese cancer patients. Jpn J Clin Oncol 27:37–41
15.
Zurück zum Zitat Maskarinec G, Shumay DM, Kakai H et al (2000) Ethnic differences in complementary and alternative medicine use among cancer patients. J Altern Complement Med 6:531–538PubMed Maskarinec G, Shumay DM, Kakai H et al (2000) Ethnic differences in complementary and alternative medicine use among cancer patients. J Altern Complement Med 6:531–538PubMed
16.
Zurück zum Zitat Kim MJ, Lee SD, Kim DR et al (2004) Use of complementary and alternative medicine among Korean cancer patients. Korean J Intern Med 19:250–256PubMed Kim MJ, Lee SD, Kim DR et al (2004) Use of complementary and alternative medicine among Korean cancer patients. Korean J Intern Med 19:250–256PubMed
17.
Zurück zum Zitat Downer SM, Cody MM, NcCluskey P et al (1994) Pursuit and practice of complementary therapies by cancer patients receiving conventional treatment. BMJ 309:86–89PubMed Downer SM, Cody MM, NcCluskey P et al (1994) Pursuit and practice of complementary therapies by cancer patients receiving conventional treatment. BMJ 309:86–89PubMed
18.
Zurück zum Zitat Richardson MA, Sanders T, Palmer JL et al (2000) Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 18:2505–2514PubMed Richardson MA, Sanders T, Palmer JL et al (2000) Complementary/alternative medicine use in a comprehensive cancer center and the implications for oncology. J Clin Oncol 18:2505–2514PubMed
19.
Zurück zum Zitat Rees RW, Feigel I, Vickers A et al (2000) Prevalence of complementary therapy use by women with breast cancer: a population-based study. Eur J Cancer 36:1359–1364 Rees RW, Feigel I, Vickers A et al (2000) Prevalence of complementary therapy use by women with breast cancer: a population-based study. Eur J Cancer 36:1359–1364
20.
Zurück zum Zitat Paltiel O, Avitzour M, Peretz T et al (2001) Determinants of the use of complementary therapies by patients with cancer. J Clin Oncol 19:2439–2448PubMed Paltiel O, Avitzour M, Peretz T et al (2001) Determinants of the use of complementary therapies by patients with cancer. J Clin Oncol 19:2439–2448PubMed
21.
Zurück zum Zitat Mochen R, Kemmler G, Schweigkofler H et al (2001) Use of alternative/complementary therapy in breast cancer patients—a psychological perspective. Support Care Cancer 9:267–274 Mochen R, Kemmler G, Schweigkofler H et al (2001) Use of alternative/complementary therapy in breast cancer patients—a psychological perspective. Support Care Cancer 9:267–274
22.
Zurück zum Zitat Burstein HJ, Gelber S, Guadagnoli E et al (1999) Use of alternative medicine by women with early-stage breast cancer. N Engl J Med 340:1733–1739CrossRefPubMed Burstein HJ, Gelber S, Guadagnoli E et al (1999) Use of alternative medicine by women with early-stage breast cancer. N Engl J Med 340:1733–1739CrossRefPubMed
23.
Zurück zum Zitat Carlsson M, Arman M, Backman M et al (2001) Perceived quality of life and coping for Swedish women with breast cancer who choose complementary medicine. Cancer Nurs 24:395–401CrossRefPubMed Carlsson M, Arman M, Backman M et al (2001) Perceived quality of life and coping for Swedish women with breast cancer who choose complementary medicine. Cancer Nurs 24:395–401CrossRefPubMed
24.
Zurück zum Zitat Cassileth BR, Lusk EJ, Guerry D et al (1991) Survival and quality of life among patients receiving unproven as compared with conventional cancer therapy. N Engl J Med, 324:1180–1185PubMed Cassileth BR, Lusk EJ, Guerry D et al (1991) Survival and quality of life among patients receiving unproven as compared with conventional cancer therapy. N Engl J Med, 324:1180–1185PubMed
25.
Zurück zum Zitat Davidson R, Geoghegan L, McLaughlin L et al Psychological characteristics of cancer patients who use complementary therapies. Psycho Oncol, (in print) Davidson R, Geoghegan L, McLaughlin L et al Psychological characteristics of cancer patients who use complementary therapies. Psycho Oncol, (in print)
Metadaten
Titel
Use of complementary and alternative medicine by patients with urologic cancer: a prospective study at a single Japanese institution
verfasst von
Koji Yoshimura
Nobufumi Ueda
Kentaro Ichioka
Yoshiyuki Matsui
Akito Terai
Yoichi Arai
Publikationsdatum
01.09.2005
Erschienen in
Supportive Care in Cancer / Ausgabe 9/2005
Print ISSN: 0941-4355
Elektronische ISSN: 1433-7339
DOI
https://doi.org/10.1007/s00520-005-0842-3

Weitere Artikel der Ausgabe 9/2005

Supportive Care in Cancer 9/2005 Zur Ausgabe

Forthcoming Meetings

Forthcoming Meetings 13/9

Adjuvante Immuntherapie verlängert Leben bei RCC

25.04.2024 Nierenkarzinom Nachrichten

Nun gibt es auch Resultate zum Gesamtüberleben: Eine adjuvante Pembrolizumab-Therapie konnte in einer Phase-3-Studie das Leben von Menschen mit Nierenzellkarzinom deutlich verlängern. Die Sterberate war im Vergleich zu Placebo um 38% geringer.

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

25.04.2024 NSCLC Nachrichten

Das Risiko für Rezidiv oder Tod von Patienten und Patientinnen mit reseziertem ALK-positivem NSCLC ist unter einer adjuvanten Therapie mit dem Tyrosinkinase-Inhibitor Alectinib signifikant geringer als unter platinbasierter Chemotherapie.

Bei Senioren mit Prostatakarzinom auf Anämie achten!

24.04.2024 DGIM 2024 Nachrichten

Patienten, die zur Behandlung ihres Prostatakarzinoms eine Androgendeprivationstherapie erhalten, entwickeln nicht selten eine Anämie. Wer ältere Patienten internistisch mitbetreut, sollte auf diese Nebenwirkung achten.

ICI-Therapie in der Schwangerschaft wird gut toleriert

Müssen sich Schwangere einer Krebstherapie unterziehen, rufen Immuncheckpointinhibitoren offenbar nicht mehr unerwünschte Wirkungen hervor als andere Mittel gegen Krebs.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.